Cancer DNA Targeting: New Gene Tech with Fewer Markers
- Researchers at UNIST and the Institute for Basic Science (IBS) have developed a refined CRISPR-based gene therapy that selectively destroys cancer cell DNA by targeting a single strand,...
- A team led by researchers from the Department of Biomedical Engineering at UNIST and the Center for Genomic Integrity at the Institute for Basic Science (IBS) has announced...
- This contrasts with previous methods, including the team's 2022 work, which required delivering over 20 guide RNAs to create multiple double-strand breaks (DSBs).
“`html
Precision Cancer Gene Therapy: New CRISPR Method Targets Single DNA Strand
Table of Contents
Researchers at UNIST and the Institute for Basic Science (IBS) have developed a refined CRISPR-based gene therapy that selectively destroys cancer cell DNA by targeting a single strand, minimizing side effects and simplifying delivery.
The Breakthrough: Single-Strand Targeting with CRISPR-Cas9 Nickase
A team led by researchers from the Department of Biomedical Engineering at UNIST and the Center for Genomic Integrity at the Institute for Basic Science (IBS) has announced a significant advancement in cancer gene therapy. Their new method utilizes CRISPR-Cas9 nickase to induce DNA single-strand breaks, coupled with PARP inhibitors (PARPi) to prevent DNA repair. This approach allows for efficient cancer cell death even in cells with a functional BRCA2 gene, a common factor in cancer resistance.
This contrasts with previous methods, including the team’s 2022 work, which required delivering over 20 guide RNAs to create multiple double-strand breaks (DSBs). The earlier approach, while effective, presented challenges in delivery and increased the risk of off-target effects – damaging healthy cells.
How It Works: Synthetic Lethality and DNA Damage
The core principle behind this innovation is synthetic lethality. By inducing single-strand breaks with Cas9-nickase and together blocking DNA repair with PARPi, cancer cells are rendered unable to tolerate the resulting DNA damage. Normal cells, with intact DNA repair mechanisms, are less affected.
The researchers demonstrated the efficacy of this method in vitro (cultured cells), in vivo (animal models using xenografts), and using patient-derived cancer organoids. Delivery was achieved using lipid nanoparticles, a common method for delivering genetic material.
Key Findings & Data
| Study Component | Key Result |
|---|---|
| Guide RNAs Required | Four synthetic guide RNAs |
| Cas9 Variant Used | Cas9-nickase |
| Repair Inhibition | PARP inhibitors (parpi) |
| Efficacy Demonstrated In | Cultured cells, in vivo xenografts, patient-derived organoids |
| BRCA2 Gene Status | Effective even with functional BRCA2 |
Implications and Future Directions
This research holds significant promise for personalized cancer therapy. By precisely targeting cancer cells while sparing healthy tissue,